SCHEMBL23294811

SCHEMBL23294811

C[C@@H]1CN(c2cccc3nc4ccc(-c5ccc(N6CCC(N(C)C)CC6)cc5)cn4c23)C[C@H](C)N1C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MET P08581 1/20 0.36
▸ PDE3B Q13370 1/20 0.36
▸ PDE3A Q14432 1/20 0.36
▸ PIK3CA P42336 5/20 0.34
▸ KCNH2 Q12809 4/20 0.34
▸ SYK P43405 1/20 0.34
▸ EIF4E P06730 1/20 0.34
▸ MKNK1 Q9BUB5 1/20 0.34
▸ MKNK2 Q9HBH9 1/20 0.34
▸ MCHR1 Q99705 3/20 0.33
▸ ACVR1 Q04771 1/20 0.32
▸ CHEK2 O96017 1/20 0.32
▸ PDCD1 Q15116 1/20 0.31
▸ CD274 Q9NZQ7 1/20 0.31
▸ MAOB P27338 1/20 0.31
▸ HTR6 P50406 1/20 0.31
▸ EED O75530 1/20 0.31
▸ HRH1 P35367 3/20 0.31
▸ CHRM1 P11229 1/20 0.31
▸ MTOR P42345 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23294861 0.91 KCNH2 (0.37) METPDE3BPDE3APIK3CAKCNH2
SCHEMBL23294791 0.88 MAOB (0.34) METPDE3BPDE3APIK3CAKCNH2
SCHEMBL23294825 0.87 PIK3CD (0.35) METPDE3BPDE3APIK3CACHEK2
SCHEMBL30116734 0.87 PIK3CD (0.35) METPDE3BPDE3APIK3CACHEK2
SCHEMBL23294787 0.86 HSD11B1 (0.35) METPDE3BPDE3APIK3CAKCNH2
SCHEMBL23294805 0.86 PIK3CA (0.39) PIK3CAKCNH2EIF4EMKNK1MKNK2
SCHEMBL23294875 0.78 MAOB (0.38) METPDE3BPDE3APIK3CAKCNH2
SCHEMBL23294917 0.78 PIK3CA (0.36) METPDE3BPDE3APIK3CAKCNH2
SCHEMBL23294818 0.77 PIK3CA (0.37) METPDE3BPDE3APIK3CAKCNH2
SCHEMBL23294788 0.77 PIK3CD (0.37) METPDE3BPDE3APIK3CAKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210128535-A1 Substituted Fused Heteroaromatic Tricyclic Compounds as Kinase Inhibitors and The Use Thereof IMPACT THERAPEUTICS, INC. (CN) 2021-05-06 — — US claimed
US-11547703-B2 Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof Impact Therapeutics (Shanghai), Inc (CN) 2023-01-10 — — US disclosed
US-20210128535-A1 Substituted Fused Heteroaromatic Tricyclic Compounds as Kinase Inhibitors and The Use Thereof IMPACT THERAPEUTICS, INC. (CN) 2021-05-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210128535-A1 Substituted Fused Heteroaromatic Tricyclic Compounds as Kinase Inhibitors and The Use Thereof CHEK2, CHEK1, ATM MET 2037/4885PDE3B 1548/4885PDE3A 2019/4885
US-11547703-B2 Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof CHEK2, CHEK1, ATM MET 2037/4885PDE3B 1548/4885PDE3A 2019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback